More Evidence for Ocular Adverse Events with GLP-1–Receptor Agonists

Glucagon-like peptide-1 (GLP-1)–receptor agonists have been associated with worsening diabetic retinopathy in randomized trials (Diabetes Care 2025; 48:S252). Recently, several observational studies have linked semaglutide to higher risk for nonarteritic anterior ischemic optic neuropathy (NEJM JW Gen Med Apr 1 2025 and JAMA Ophthalmol 2025; 143:267). Now, Canadian researchers have examined whether use of GLP-1 agonists is associated with another eye disorder, neovascular age-related macular degeneration (nAMD). Using a large database, they identified older patients (age, ≥66) who had diabetes and no history of nAMD. Among these, 46,000 who had been using GLP-1 agonists (mostly semaglutide) for at least 6 months were compared with 93,000 pr…